Anzeige
Mehr »
Sonntag, 14.06.2026 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von Oslo Børs

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
MiFjord Defence Group ASA - New share capital registered
MiContemplated secondary placement of existing shares in SED Energy Holdings Plc
MiCADELER A/S: REPORTING ON TRANSACTIONS IN CADELER A/S SHARES BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
MiZaptec ASA: Annual general meeting completed
MiLifecare ASA: Mandatory notification of trade
MiEndúr ASA - Successful completion of acquisition of Enviro Entreprenør AS
MiOrkla ASA: Mandatory notification of trade primary insiders
MiBorr Drilling Limited: Major Shareholding Notification
MiVeidekke ASA: Road maintenance contracts worth NOK 1.5 billion
MiZalaris ASA: NOTIFICATION OF MAJOR HOLDINGS
MiStadshypotek AB (publ): Rate fixing STHY14
MiZalaris ASA: Major Shareholding Disclosure - ZAL NO
MiTieto Oyj: Composition of Tieto's Shareholders' Nomination Board
MiAWILCO LNG ASA - New name ALNG ASA registered
MiDellia Group ASA - Key information relating to share split and change of ISIN
MiAvinor AS: Strong growth in passenger numbers - Bergen is an important driver
MiKINGDOM OF NORWAY: Result of issuing auction NGB 04/2028 and NGB 06/2036
MiS.D. Standard ETC Plc: SDSD- Minutes from Annual General Meeting
MiTelenor ASA: Telenor acquires Enivest in Western Norway
MiSpareBank 1 Østlandet (SPOL): Contemplating issuance of Additional Tier 1 capital
MiFjord Defence Group ASA - Fjord Defence Marine AS wins framework agreement worth up to NOK 113 million
MiMagnora ASA: New share buyback programme
MiOrkla ASA: Status share buy-back programme
MiSentia ASA: Contract Awarded for Full Rehabilitation of Stenersgata 1 Phase 2
MiLifecare ASA: Lifecare completes first six-month implant evaluation with continued functionality and no adverse biological response